

# Circulating Dopamine and C-Peptide Levels in Fasting Nondiabetic Hypertensive Patients

The Graz Endocrine Causes of Hypertension study

ANDREAS TOMASCHITZ, MD<sup>1</sup>  
 EBERHARD RITZ, MD<sup>2</sup>  
 KATHARINA KIENREICH, MD<sup>3</sup>  
 BURKERT PIESKE, MD<sup>1</sup>  
 WINFRIED MÄRZ, MD<sup>4,5,6</sup>

BERNHARD O. BOEHM, MD<sup>7</sup>  
 CHRISTIANE DRECHSLER, MD, PHD<sup>8</sup>  
 ANDREAS MEINITZER, PHD<sup>4</sup>  
 STEFAN PILZ, MD<sup>3,9</sup>

**OBJECTIVE**—Accumulating evidence supports a potential role for dopamine in the regulation of insulin secretion. We examined the association between circulating dopamine and C-peptide concentrations using data from the Graz Endocrine Causes of Hypertension (GECOH) study.

**RESEARCH DESIGN AND METHODS**—After 12 h of fasting, we measured plasma dopamine and serum C-peptide levels and established determining factors of insulin secretion in 201 nondiabetic hypertensive patients (mean age 48.1 ± 16.0 years; 61.7% women).

**RESULTS**—Mean dopamine and C-peptide concentration were 33.4 ± 38.6 pg/mL and 3.1 ± 2.7 ng/mL, respectively. A strong and inverse correlation was observed between dopamine and C-peptide levels ( $r = -0.423$ ,  $P < 0.001$ ). There was no significant relationship between C-peptide, plasma epinephrine, and norepinephrine. C-peptide levels decreased steadily and significantly from tertile 1 of dopamine (3.6 ng/mL [95% CI 2.9–4.1]) to tertile 3 (1.6 ng/mL [1.5–2.7]),  $P < 0.001$  after multivariate adjustment.

**CONCLUSIONS**—The inverse association between dopamine and C-peptide highlights the need to evaluate whether dopamine could be effective for modulating endocrine pancreatic function.

*Diabetes Care* 35:1771–1773, 2012

Circulating dopamine is 1) derived from sympathetic noradrenergic nerves and 2) is synthesized within the adrenal medulla and in amine precursor uptake and decarboxylation cells (i.e., in the kidney and endocrine pancreas) (1).

Accumulating evidence supports a role for catecholamines in the regulation

of insulin secretion (2). Lerner and Porte (3) observed the inhibitory effects of epinephrine (and norepinephrine) on the acute pancreatic insulin response to glucose but not during prolonged hyperglycemia. Animal studies documented an inhibition of pancreatic insulin secretion in response to dopamine administration

(4). Mice lacking D2 dopamine receptors showed an impaired glucose-related insulin release, which results in glucose intolerance (5).

In view of the evidence for the inhibitory effects of dopamine on insulin secretion, we hypothesize that circulating dopamine is inversely related to C-peptide levels, reflecting prehepatic insulin secretion, in fasting nondiabetic adult hypertensive patients (6).

## RESEARCH DESIGN AND METHODS

The Graz Endocrine Causes of Hypertension (GECOH) study population comprises adult diabetic and nondiabetic patients (aged ≥18 years), who have routinely been referred to our outpatient clinic for screening for endocrine hypertension (6). Between February 2009 and November 2011, 224 white study participants were enrolled. Main inclusion criterion was arterial hypertension. The exclusion criteria have been described in the published study protocol (6). Patients taking antipsychotic drugs and/or with diagnosed pheochromocytoma or Cushing's disease, which are both known to have impact on dopamine and insulin secretion, were excluded from the analysis. Finally, after exclusion of 23 patients with diabetes (0.9% with type 1 diabetes and 9.4% with type 2 diabetes classified according to American Diabetes Association criteria), 201 participants remained eligible for the analysis (7). Blood samplings were performed in the morning (8:00–11:00 A.M.) after the patients had been seated for 10 min.

Extensive laboratory and clinical assessments were performed after at least 12 h of fasting. Written informed consent was obtained from all study participants. The GECOH study complies with the Declaration of Helsinki.

## Laboratory methods

The laboratory methods have been described in detail in a previous report (6). Measurement of plasma dopamine concentrations was performed using a radioimmunoassay

From the <sup>1</sup>Department of Internal Medicine, Division of Cardiology, Medical University of Graz, Graz, Austria; the <sup>2</sup>Department of Medicine, Division of Nephrology, University Hospital Heidelberg, Heidelberg, Germany; the <sup>3</sup>Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria; the <sup>4</sup>Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria; the <sup>5</sup>Synlab Academy, Synlab Services, Mannheim, Germany; the <sup>6</sup>Mannheim Institute of Public Health, Ruperto Carola University Heidelberg, Medical Faculty Mannheim, Mannheim, Germany; the <sup>7</sup>Division of Endocrinology, Diabetes, and Metabolism, Graduate School of Molecular Diabetology and Endocrinology, Ulm University, Ulm, Germany; the <sup>8</sup>Department of Medicine, Division of Nephrology, University of Würzburg, Würzburg, Germany; and the <sup>9</sup>Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands.

Corresponding authors: Andreas Tomaschitz, andreas.tomaschitz@gmx.at, and Stefan Pilz, stefan.pilz@chello.at. Received 7 December 2011 and accepted 27 March 2012.

DOI: 10.2337/dc11-2384

A.T. and S.P. contributed equally to this work and are principal investigators of the Graz Endocrine Causes of Hypertension study.

© 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

(reference value <100 pg/mL, TriCat RIA; DRG International, Marburg, Germany). Epinephrine and norepinephrine were determined by the TriCat-RIA (reference limit <100 and <600 pg/mL, respectively). Serum C-peptide concentrations were determined by a chemoluminescence sandwich immunoassay (ADVIA Centaur; Siemens Healthcare Diagnostics, Tarrytown, NY).

**Statistical analysis**

Pearson correlation analyses were performed to analyze the associations between circulating C-peptide, dopamine, epinephrine, and norepinephrine levels. One-way ANCOVA followed by Bonferroni post hoc tests was used to compare mean C-peptide values across sex-specific tertiles of the dopamine concentration after consideration of age, BMI, HbA<sub>1c</sub>, fasting glucose, triglycerides, LDL cholesterol, HDL cholesterol, serum albumin, C-reactive protein, systolic blood pressure, glomerular filtration rate, epinephrine, norepinephrine, serum cortisol, active smoking, regular alcohol consumption, and detailed antihypertensive medication and statin use as potential confounders. All data were analyzed using the SPSS software package (version 17.0; SPSS, Chicago, IL).  $P < 0.05$  was considered statistically significant.


**RESULTS**—The mean age of the 201 nondiabetic hypertensive white study participants (61.7% women) was  $48.1 \pm 16.0$  years. Plasma dopamine concentration was  $33.4 \pm 38.6$  pg/mL, and serum C-peptide concentration was  $3.1 \pm 2.7$  ng/mL.

Pearson correlation analysis revealed a strong and inverse association between C-peptide and dopamine concentrations ( $r = -0.42$ ,  $P < 0.001$ ). Sex-stratified subgroup analysis revealed a strong correlation between C-peptide and dopamine in either sex (Fig. 1A and B). No significant correlation was seen between C-peptide and norepinephrine ( $r = 0.06$ ,  $P = 0.198$ ) and epinephrine ( $r = -0.05$ ,  $P = 0.196$ ) levels. Circulating dopamine correlated positively with norepinephrine levels ( $r = 0.19$ ,  $P = 0.022$ ). A strong positive correlation was seen between the insulin-to-C-peptide molar ratio (mean  $0.07 \pm 0.04$  pmol/L:pmol/L) and plasma dopamine ( $r = 0.30$ ,  $P < 0.001$ ), although this association might be mainly attributed to the strong correlation between C-peptide and dopamine. Only borderline significance was found between serum

insulin and dopamine ( $r = -0.16$ ,  $P = 0.057$ ).

In fully adjusted ANCOVA, we noted a significant decrease in C-peptide values ( $P < 0.001$ ) across increasing values of dopamine concentration (in sex-specific tertiles) in the entire cohort. The absolute mean difference in C-peptide levels between dopamine concentration tertile 1 (3.6 ng/mL) and tertile 3 (1.6 ng/mL) was 2.0 ng/mL.

**CONCLUSIONS**—We demonstrate that higher dopamine levels are strongly related to lower serum C-peptide values in plasma of 12-h postabsorptive nondiabetic hypertensive patients. The inverse association between C-peptide and dopamine persisted after consideration of multiple confounders. The present observation implicates a potential role for peripheral dopamine in modulating insulin secretion and  $\beta$ -cell function in fasting conditions.



**Figure 1**—Scatter plots showing the bivariate Pearson correlation between plasma dopamine and serum C-peptide concentration levels in male (A) and female (B) participants, respectively.

There has been growing interest in the impact of dopamine on insulin secretion. Studies in healthy volunteers revealed increased insulin levels after dopamine administration, but these studies were limited by small sample size (8,9). Rubí et al. (4) identified D2 dopamine receptors, which are activated by extracellular (circulating) dopamine, in insulin granules of human  $\beta$ -cells. Activation of these receptors results in an inhibition of glucose-related cell membrane depolarization and insulin exocytosis (4,5,10). Shankar et al. (10) demonstrated that insulin secretion is stimulated at low and inhibited at high dopamine concentrations. These studies therefore, by the majority, support our findings. However, in contrast to previous studies, we neither observed lower dopamine levels nor a weaker association between dopamine and C-peptide levels in diabetic compared with nondiabetic participants (data not shown) (11).

In line with our findings, several human studies documented metabolic alterations by neuroleptic drugs as a result of interference with dopaminergic pathways (12). Several but not all studies documented that the use of the dopamine agonist, bromocriptine, is paralleled by decreased insulinemia (13–15).

We found no association between plasma norepinephrine and serum C-peptide levels. This finding points to dopamine but not to norepinephrine as a major mediator of insulin secretion. Because dopamine, serum cortisol, epinephrine, and norepinephrine clearly were below the upper reference limit, we suggest that our findings are not primarily triggered by an increased stress response.

Although blood was drawn after a 10-min period in the sitting position, we cannot conclude that this resting period was adequate to reliably interpret circulating dopamine levels. In addition, we analyzed nondiabetic hypertensive white subjects; therefore, generalizations to other populations cannot be made. The

observational study design precludes conclusions with regard to causal relationships.

In summary, higher circulating dopamine is independently related to lower serum C-peptide. Additional studies are warranted to delineate the effects of dopamine on insulin secretion.

**Acknowledgments**—A.T. is partially funded by the European Union Project MASCARA (Markers for Sub-Clinical Cardiovascular Risk Assessment; THEME HEALTH.2011.2.4.2-2; Grant 278249). K.K. is supported by funding from the Austrian National Bank (Jubiläumfond: Projects 13878 and 13905).

No potential conflicts of interest relevant to this article were reported.

A.T. and S.P. wrote the manuscript, researched data, and are the principal investigators. E.R. reviewed and edited the manuscript. K.K. researched data and reviewed and edited the manuscript. B.P., W.M., B.O.B., C.D., and A.M. reviewed and edited the manuscript and contributed to the discussion. A.T. and S.P. are the guarantors of this work and, as such, had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank the whole staff of the outpatient clinic and the laboratory at the Department of Endocrinology and Metabolism at the Medical University of Graz for supporting them with the GECO study.

## References

- Goldstein DS, Holmes C. Neuronal source of plasma dopamine. *Clin Chem* 2008;54:1864–1871
- Quickel KE Jr, Feldman JM, Lebovitz HE. Inhibition of insulin secretion by serotonin and dopamine: species variation. *Endocrinology* 1971;89:1295–1302
- Lerner RL, Porte D Jr. Epinephrine: selective inhibition of the acute insulin response to glucose. *J Clin Invest* 1971;50:2453–2457
- Rubí B, Ljubicic S, Pournourmohammadi S, et al. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. *J Biol Chem* 2005;280:36824–36832
- García-Tornadú I, Ornstein AM, Chamson-Reig A, et al. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. *Endocrinology* 2010;151:1441–1450
- Pilz S, Tomaschitz A, Stepan V, et al. Graz Endocrine Causes of Hypertension (GECO) Study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism. *BMC Endocr Disord* 2009;9:11
- American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2009;32(Suppl. 1):S62–S67
- Martin G, Forte P, Luchsinger A, et al. Dopamine-induced antihypertensive effects and plasma insulin rise are blocked by metoclopramide in labetalol-treated patients. *J Clin Pharmacol* 1994;34:91–94
- Ruttimann Y, Schutz Y, Jéquier E, Lemarchand T, Chiolléro R. Thermogenic and metabolic effects of dopamine in healthy men. *Crit Care Med* 1991;19:1030–1036
- Shankar E, Santhosh KT, Paulose CS. Dopaminergic regulation of glucose-induced insulin secretion through dopamine D2 receptors in the pancreatic islets in vitro. *IUBMB Life* 2006;58:157–163
- de Leeuw van Weenen JE, Parlevliet ET, Maechler P, et al. The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. *Biochem Pharmacol* 2010;79:1827–1836
- Lebovitz HE. Metabolic consequences of atypical antipsychotic drugs. *Psychiatr Q* 2003;74:277–290
- Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. *Diabetes Care* 2000;23:1154–1161
- Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. *Diabetes Care* 1996;19:667–670
- Wasada T, Kawahara R, Iwamoto Y. Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients. *Diabetes Care* 2000;23:1039–1040